Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 22, 2026, 3:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 87 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: HFA MDI Clear all
Completed Phase 3 Interventional

New Combination Inhaler (FlutiForm HFA MDI 100/10 µg and 250/10 µg) Versus Fluticasone and Formoterol Administered Alone, and Placebo in Patients With Moderate to Severe Asthma

NCT00393952
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone propionate/Formoterol fumarate 250/10, Placebo, Fluticasone propionate/Formoterol fumarate 100/10, Fluticasone propionate 250, Formoterol fumarate 10
Drug
Lead sponsor
SkyePharma AG
Industry
Eligibility
12 Years and older
Enrollment
557 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
62
States / cities
Pell City, Alabama • Glendale, Arizona • Phoenix, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2011 · Synced Sep 22, 2026, 3:38 AM EDT
Completed Phase 3 Interventional

Evaluation of Two Doses of QVAR by Breath Operated and Metered Dose Inhalers in Asthmatic Children

NCT00094016
View directory record Official record
Conditions
Asthma
Interventions
beclomethasone dipropionate
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
5 Years to 11 Years
Enrollment
440 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
37
States / cities
Huntington Beach, California • Long Beach, California • Mission Viejo, California + 31 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2021 · Synced Sep 22, 2026, 3:38 AM EDT
Completed Phase 2 Interventional Results available

A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler (Puffer) in Adolescents and Adults Who Have Asthma That is Not Controlled by High Dose Inhaled Corticosteroid Asthma Medications

NCT01576718
View directory record Official record
Conditions
Asthma
Interventions
Fp MDPI, Placebo MDPI, Flovent Diskus, albuterol/salbutamol
Drug · Other
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years and older
Enrollment
889 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
148
States / cities
Birmingham, Alabama • Homewood, Alabama • Goodyear, Arizona + 114 more
Source: ClinicalTrials.gov public record
Updated May 7, 2018 · Synced Sep 22, 2026, 3:38 AM EDT
Terminated Phase 2 Interventional Results available

Study on BI 54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Low Dose Inhaled Corticosteroid (ICS)

NCT01397201
View directory record Official record
Conditions
Asthma
Interventions
Placebo, BI 54903, Fluticasone propionate
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
12 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
41
States / cities
Fountain Valley, California • Fullerton, California • Huntington Beach, California + 38 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2022 · Synced Sep 22, 2026, 3:38 AM EDT
Completed Phase 2 Interventional Results available

PT001 MDI Versus Atrovent Study in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

NCT01350128
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
PT001 MDI, Ipratropium Bromide HFA Inhalation Aerosol, Placebo MDI
Drug · Other
Lead sponsor
Pearl Therapeutics, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
8
States / cities
Panama City, Florida • Winter Park, Florida • Cherry Hill, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2018 · Synced Sep 22, 2026, 3:38 AM EDT
Completed Phase 3 Interventional Results available

Study Comparing Budesonide Hydrofluoroalkane (HFA) vs Chlorofluorocarbon (CFC) Pressurized Metered Dose Inhalers (pMDI) in Patients With Mild to Moderate Asthma

NCT00667992
View directory record Official record
Conditions
Asthma
Interventions
Budesonide HFA, Budesonide CFC
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
King of Prussia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 6, 2012 · Synced Sep 22, 2026, 3:38 AM EDT
Completed Phase 2 Interventional Results available

A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler in Adolescents and Adults Who Have Asthma That is Not Controlled by Asthma Medications Not Containing Steroids

NCT01479621
View directory record Official record
Conditions
Asthma
Interventions
Fp MDPI, Flovent Diskus, albuterol/salbutamol, Placebo MDPI
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years and older
Enrollment
909 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
129
States / cities
Homewood, Alabama • Goodyear, Arizona • Scottsdale, Arizona + 104 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2017 · Synced Sep 22, 2026, 3:38 AM EDT
Completed Phase 2 Interventional

Safety and Tolerability Study of Levalbuterol HFA Compared to Racemic Albuterol HFA in Subjects With Asthma

NCT00685022
View directory record Official record
Conditions
Asthma
Interventions
Levalbuterol HFA MDI followed by Racemic albuterol HFA MDI, Racemic Albuterol followed by levalbuterol HFA MDI
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
12 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003
U.S. locations
3
States / cities
Encinitas, California • North Dartmouth, Massachusetts • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 21, 2012 · Synced Sep 22, 2026, 3:38 AM EDT
Completed Phase 3 Interventional

Epinephrine Inhalation Aerosol USP: For Evaluation Of Efficacy And Safety In Asthma Patients

NCT01357642
View directory record Official record
Conditions
Asthma
Interventions
epinephrine inhalation aerosol, Placebo
Drug
Lead sponsor
Amphastar Pharmaceuticals, Inc.
Industry
Eligibility
12 Years to 75 Years
Enrollment
373 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
33
States / cities
Costa Mesa, California • Los Angeles, California • Mission Viejo, California + 30 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2016 · Synced Sep 22, 2026, 3:38 AM EDT
Completed Phase 3 Interventional

Comparison of New Combination Inhaler (FlutiForm HFA MDI 100/10 µg) Versus Fluticasone and Formoterol Administered Alone, and Placebo, in Patients With Asthma

NCT00393991
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone propionate/formoterol fumarate 100/10, Fluticasone propionate 100, Formoterol fumarate 10, Placebo
Drug
Lead sponsor
SkyePharma AG
Industry
Eligibility
12 Years and older
Enrollment
475 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
47
States / cities
Pell City, Alabama • Scottsdale, Arizona • Cypress, California + 42 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2011 · Synced Sep 22, 2026, 3:38 AM EDT
Completed Phase 3 Interventional

Comparison of Two Bronchodilator Inhalers in Adolescents and Adults With Exercise-Induced Asthma

NCT00085774
View directory record Official record
Conditions
Exercise-induced Bronchospasm
Interventions
albuterol aerosol by HFA MDI, albuterol aerosol by HFA BOI, placebo aerosol by HFA
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years to 40 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004
U.S. locations
3
States / cities
Denver, Colorado • Englewood, Colorado • Lakewood, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 23, 2021 · Synced Sep 22, 2026, 3:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Pharmacokinetics of Halix(TM) Albuterol Unit Dose Disposable Inhaler Versus Albuterol MDI

NCT03373409
View directory record Official record
Conditions
Asthma
Interventions
Albuterol DPI 90mcg, Albuterol DPI 180mcg, Albuterol HFA MDI
Drug
Lead sponsor
Concentrx Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 29, 2019 · Synced Sep 22, 2026, 3:38 AM EDT
Completed Phase 2 Interventional

Comparative Effectiveness of a Breath-operated Albuterol Inhaler in Asthma Patients With Poor Inhaler Technique

NCT00054964
View directory record Official record
Conditions
Asthma
Interventions
Albuterol HFA-BOI, Albuterol HFA-MDI
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 29, 2021 · Synced Sep 22, 2026, 3:38 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Evaluation of Efficacy and Safety for Single Dose of E004 in Children With Asthma

NCT01737905
View directory record Official record
Conditions
Asthma
Interventions
Epinephrine HFA-MDI (E004), Placebo-HFA
Drug
Lead sponsor
Amphastar Pharmaceuticals, Inc.
Industry
Eligibility
4 Years to 11 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
6
States / cities
Cypress, California • Medford, Oregon • Portland, Oregon + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2016 · Synced Sep 22, 2026, 3:38 AM EDT
Completed Phase 3 Interventional Results available

Study to Assess Bronchospasm Potentially Induced by Next-Generation Propellant vs HFA Propellant in an MDI in Participants With Well/Partially Controlled Asthma

NCT05850494
View directory record Official record
Conditions
Asthma
Interventions
HFA MDI, HFO MDI
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 45 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
4
States / cities
North Dartmouth, Massachusetts • St Louis, Missouri • Raleigh, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Sep 22, 2026, 3:38 AM EDT
Completed Phase 3 Interventional Results available

A 12-week Safety and Efficacy Study of Beclomethasone Dipropionate (80 and 160 mcg/Day) Delivered Via Breath-Actuated Inhaler (BAI) in Patients >=12 Years Old With Persistent Asthma

NCT02040779
View directory record Official record
Conditions
Persistent Asthma
Interventions
Beclomethasone dipropionate breath-actuated inhaler, Placebo breath-actuated inhaler, albuterol/salbutamol
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years and older
Enrollment
273 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
47
States / cities
Huntington Beach, California • Mission Viejo, California • Orange, California + 41 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Sep 22, 2026, 3:38 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy of Albuterol Administered by the Halix™ Dry Powder Inhaler in Subjects With Asthma

NCT03643874
View directory record Official record
Conditions
Asthma
Interventions
Halix albuterol 90 mcg, albuterol HFA MDI 90 mcg
Drug
Lead sponsor
Concentrx Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 29, 2019 · Synced Sep 22, 2026, 3:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Assess the Lung Exposure Bioequivalence of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI With Next-Generation Propellant Compared With BGF MDI With HFA Propellant

NCT05477108
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Treatment A (BGF MDI HFO with oral activated charcoal), Treatment B (BGF MDI HFA with oral activated charcoal)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 60 Years
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 27, 2025 · Synced Sep 22, 2026, 3:38 AM EDT
Completed Phase 4 Interventional

Impact of Anti-static Chamber/Mask

NCT00307970
View directory record Official record
Conditions
Asthma
Interventions
HFA FP MDI, conventional chamber/mask; anti-static chamber/mask
Drug · Device
Lead sponsor
University of Florida
Other
Eligibility
1 Year to 6 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 19, 2011 · Synced Sep 22, 2026, 3:38 AM EDT
Completed Phase 3 Interventional Results available

Combivent Respimat 1-year Safety Study in Patients With Chronic Obstructive Pulmonary Disease

NCT01019694
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Combivent CFC-MDI, Combivent Respimat 20/100 mcg, Atrovent HFA 42 mcg + Albuterol HFA 200 mcg
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
470 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
55
States / cities
Jasper, Alabama • Mobile, Alabama • Mesa, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2014 · Synced Sep 22, 2026, 3:38 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of FP MDPI Compared With FS MDPI in Adolescent and Adult Patients With Persistent Asthma

NCT02141854
View directory record Official record
Conditions
Asthma
Interventions
FS MDPI, Fp MDPI, Placebo MDPI, Albuterol/salmeterol HFA MDI
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years and older
Enrollment
882 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
85
States / cities
Birmingham, Alabama • Little Rock, Alaska • Phoenix, Arizona + 74 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Sep 22, 2026, 3:38 AM EDT
Completed Phase 3 Interventional Results available

A Safety, Efficacy and Tolerability Study in Pediatric Subjects With Asthma

NCT00809757
View directory record Official record
Conditions
Asthma
Interventions
Levalbuterol, Levalbuterol UDV TID, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
Up to 48 Months
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
46
States / cities
Little Rock, Arkansas • Cypress, California • Long Beach, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2014 · Synced Sep 22, 2026, 3:38 AM EDT
Completed Phase 3 Interventional

Comparison of New Combination Inhaler (FlutiForm HFA MDI 100/10 µg) Versus Fluticasone & Formoterol Administered Alone in Patients With Asthma

NCT00394199
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone propionate/Formoterol Fumarate 100/10, Fluticasone propionate 100, Formoterol fumarate 10
Drug
Lead sponsor
SkyePharma AG
Industry
Eligibility
12 Years and older
Enrollment
357 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
29
States / cities
Birmingham, Alabama • Mission Viejo, California • Orange, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2011 · Synced Sep 22, 2026, 3:38 AM EDT
Completed Phase 1 Interventional

Acute Bronchodilator Effect of Inhaled Albuterol Sulfate and Ipratropium Bromide in Patients With Stable COPD

NCT03480997
View directory record Official record
Conditions
COPD
Interventions
Albuterol Sulfate and Ipratropium Bromide, Albuterol Sulfate
Combination Product
Lead sponsor
Pneuma Respiratory, Inc
Industry
Eligibility
40 Years to 80 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Hickory, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 28, 2018 · Synced Sep 22, 2026, 3:38 AM EDT